Top U.S. Defense Stocks to Watch According to Jefferies Analysis
Investing.com -- Arcus Biosciences (NYSE:RCUS) stock surged 13% Monday after the company reported impressive survival data from its Phase 2 gastric cancer trial, showing patients lived significantly longer than would typically be expected with standard treatments.
The clinical-stage biopharmaceutical company announced that patients in Arm A1 of its EDGE-Gastric study achieved a median overall survival of 26.7 months when treated with the company’s experimental combination of domvanalimab, zimberelimab and chemotherapy. The data will be presented at the upcoming European Society for Medical Oncology Congress.
According to Dr. Sun Young Rha, a professor at Yonsei University in Korea, "It is impressive to see that 50 percent of the patients enrolled in Arm A1 of the EDGE-Gastric study went on to live for more than two years. A 26.7-month median overall survival is well beyond what would be required to demonstrate clinically meaningful benefit over standard of care."
The trial evaluated patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. Efficacy was observed across all PD-L1 subgroups, with a confirmed objective response rate of 59% overall and 69% in patients with high PD-L1 expression.
Mizuho analyst Salim Syed wrote, "This is the first OS disclosure for the study; and seems far superior to benchmark studies at this point (by 10+mo in some cases) -- and reads positively, in our view, to dom’s Ph3 STAR-221 (recall, same combo in same upper GI setting), expected to read out in 2026. We’d argue little to no credit in the stock for dom up to this point."
The company is currently evaluating the same treatment combination in the Phase 3 STAR-221 study in the same patient population. Both domvanalimab and zimberelimab remain investigational molecules that have not yet received regulatory approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.